C4 Therapeutics' pipeline ... reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts.

In other recent news, C4 Therapeutics has made significant strides in its 2025 clinical trials, particularly with the ...

A particular protein involved in regulating C4 photosynthesis genes turns on an extra group of leaf cells. This allows plants using C4 to produce more energy and adapt to environmental stressors ...